Experience

Aleta Biotherapeutics

• United States
• Biotechnology
• 1 - 100 Employee

• Acting CEO, President & CSO

  • Jan 2022 - 2 years

  Natick, Massachusetts, United States

• President & CSO

  • Jan 2016 - Feb 2022

  Natick, MA



SugarCone Biotech Consultants LLC

• Founder & Principal

  • 2012 - 2016



X-Rx Discovery

• Chief Scientific Officer/Executive Consultant

  • Sep 2012 - Jan 2014

  Waltham, MA X-Rx Discovery develops novel therapeutics for oncology, inflammatory and metabolic diseases. As CSO I created and executed preclinical development campaigns for a suite of stunning NCEs directed to novel targets. Critical goals include developing and managing the pipeline, building a network of collaborations that will help assess therapeutic activity, driving compound development through lead optimization and validation using in vitro, in vivo and toxicology assays and models, and building a… Show more X-Rx Discovery develops novel therapeutics for oncology, inflammatory and metabolic diseases. As CSO I created and executed preclinical development campaigns for a suite of stunning NCEs directed to novel targets. Critical goals include developing and managing the pipeline, building a network of collaborations that will help assess therapeutic activity, driving compound development through lead optimization and validation using in vitro, in vivo and toxicology assays and models, and building a compelling vision for the therapeutic use of X-Rx Discovery's novel drugs. Show less



Biogen

• United States
• Biotechnology Research
• 700 & Above Employee

• Principal Scientist

  • May 1995 - May 2012

  Cambridge, Massachusetts Summary. Strategic, program, and project leadership, with broad responsibility for the analysis and advancement of therapeutic small molecule and biological candidate molecules, including discovery, validation and IND-enabling studies. Managed programs across Discovery Research, Medicinal and Protein Chemistry, Pre-Clinical, Clinical and Commercial operations to deliver critical analyses, linked to timelines and milestones, to enable efficient and informed program development. Recent… Show more Summary. Strategic, program, and project leadership, with broad responsibility for the analysis and advancement of therapeutic small molecule and biological candidate molecules, including discovery, validation and IND-enabling studies. Managed programs across Discovery Research, Medicinal and Protein Chemistry, Pre-Clinical, Clinical and Commercial operations to deliver critical analyses, linked to timelines and milestones, to enable efficient and informed program development. Recent Positions and Responsibilities. - Head, Translational ImmunoBiology Modeling - Principal Investigator, Immunobiology and Immunopharmacology - Member, Immunobiology and Rheumatology Strategic Leadership - Co-Lead, Fibrosis Strategic Review - Co-Lead, Lupus and Lupus Nephritis Strategic Area Review - Member Scientific Diligence for Biogen Idec Corporate Strategy - Lead R&D scientist, Tysabritm post-registrational studies and JC Virus mitigation - Head, Cardiovascular Inflammation Discovery Show less



Repligen Corporation

• United States
• Biotechnology Research
• 700 & Above Employee

• Associate Scientist, Departments of Molecular Biology and Molecular Immunology

  • 1986 - 1995

  Cambridge, Massachusetts Immunology Staff Scientist: T Cell Costimulation - Led structure/function analyses of CD28 ligands B7-1 and B7-2 - Cloned and patented a novel form of CTLA4-Ig fusion protein for use in transplantation - Cloned and patented novel T cell activation proteins, fusion proteins and antibodies - Managed core facility for DNA sequencing and oligonucleotide synthesis